Physician profile
Michael D White
NPI 1265600357
$275,610.98
in general payments reported to CMS, 2019-2025
40 companies · $137K in 2025
The $137K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11K · 2022: $20K · 2023: $46K · 2024: $62K · 2025: $137K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $153K · Travel and Lodging: $30K · Consulting Fee: $28K · Food and Beverage: $26K · Honoraria: $7,600 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $152,977.50 |
| Travel and Lodging | $29,954.72 |
| Consulting Fee | $27,853.24 |
| Food and Beverage | $26,466.65 |
| Honoraria | $7,600.00 |
| Education | $235.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $107,685.00 | 2021-2025 | Ams 700 Cxr Rte Kit, Ams 700, General - Erectile Dysfunction |
| Janssen Biotech, INC. | $96,927.20 | 2021-2025 | Rybrevant, Carvykti, Erleada |
| Endo Pharmaceuticals INC. | $18,119.78 | 2021-2024 | Xiaflex, Aveed, Edex |
| Endo USA, INC. | $13,878.30 | 2024-2025 | Xiaflex |
| Accord Healthcare, INC. | $12,584.17 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $7,145.87 | 2023-2025 | Erleada |
| Coloplast Corp | $6,070.91 | 2021-2025 | Titan |
| Verity Pharmaceuticals INC. | $4,129.32 | 2023-2025 | Tlando, Trelstar |
| Astrazeneca Pharmaceuticals Lp | $2,448.60 | 2022-2025 | Lynparza, Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $882.94 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $646.41 | 2024-2025 | Adstiladrin |
| Medtronic, INC. | $641.33 | 2021-2024 | Interstim |
| Sumitomo Pharma America, INC. | $625.05 | 2023-2025 | Orgovyx, Gemtesa |
| Teleflex LLC | $526.39 | 2021-2024 | Urolift |
| Astellas Pharma US INC | $459.77 | 2021-2025 | Xtandi, Veozah |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.